Search research articles
Contact Us
Filters
Showing results (1-10 of 35) with videos related to
Page
of 4
Sort By:
Cancers
|
July 24, 2021
Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy
Aya Saleh, Ruth Perets
Cancer Research
|
December 17, 2015
It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research
Ruth Perets, Ronny Drapkin
International Journal of Molecular Sciences
|
July 9, 2022
PAX8 in the Junction between Development and Tumorigenesis
Reli Rachel Kakun, Zohar Melamed, Ruth Perets
Critical Reviews in Oncology/Hematology
|
May 16, 2018
Glucocorticoids as an adjunct to oncologic treatment in solid malignancies - Not an innocent bystander
Corinne Maurice-Dror, Ruth Perets, Gil Bar-Sela
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
November 3, 2020
Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Tarek Taha, Ari Reiss, Amnon Amit, et al.
Investigational New Drugs
|
January 20, 2020
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients
Alberto A Gabizon, Esther Tahover, Talia Golan, et al.
The American Journal of Surgical Pathology
|
April 24, 2010
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma
Anna R Laury, Jason L Hornick, Ruth Perets, et al.
Plos One
|
October 12, 2012
Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer
Ruth Perets, Tommy Kaplan, Ilan Stein, et al.
Oncogene
|
July 10, 2021
PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer
Basem Fares, Liron Berger, Einav Bangiev-Girsh, et al.
The Oncologist
|
January 27, 2018
Mutant <i>KRAS</i> Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
Ruth Perets, Orli Greenberg, Talia Shentzer, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 35) with videos related to
Sort By:
Page
of 4
Cancers
|
July 24, 2021
Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy
Aya Saleh, Ruth Perets
Cancer Research
|
December 17, 2015
It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research
Ruth Perets, Ronny Drapkin
International Journal of Molecular Sciences
|
July 9, 2022
PAX8 in the Junction between Development and Tumorigenesis
Reli Rachel Kakun, Zohar Melamed, Ruth Perets
Critical Reviews in Oncology/Hematology
|
May 16, 2018
Glucocorticoids as an adjunct to oncologic treatment in solid malignancies - Not an innocent bystander
Corinne Maurice-Dror, Ruth Perets, Gil Bar-Sela
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
November 3, 2020
Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Tarek Taha, Ari Reiss, Amnon Amit, et al.
Investigational New Drugs
|
January 20, 2020
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients
Alberto A Gabizon, Esther Tahover, Talia Golan, et al.
The American Journal of Surgical Pathology
|
April 24, 2010
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma
Anna R Laury, Jason L Hornick, Ruth Perets, et al.
Plos One
|
October 12, 2012
Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer
Ruth Perets, Tommy Kaplan, Ilan Stein, et al.
Oncogene
|
July 10, 2021
PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer
Basem Fares, Liron Berger, Einav Bangiev-Girsh, et al.
The Oncologist
|
January 27, 2018
Mutant <i>KRAS</i> Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
Ruth Perets, Orli Greenberg, Talia Shentzer, et al.
Page
of 4